Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599612 | 0.77 | PARP1 (0.44) | ALDH1A1LMNAGPR17GAAPARP1 | |
| SCHEMBL3662908 | 0.77 | — | — | |
| SCHEMBL7036571 | 0.72 | — | — | |
| SCHEMBL7598825 | 0.71 | F13A1 (0.44) | GAA | |
| SCHEMBL30132218 | 0.69 | F13A1 (0.51) | MAPTGAA | |
| SCHEMBL30132260 | 0.68 | F13A1 (0.54) | MAPTLMNAGAA | |
| SCHEMBL30132305 | 0.68 | F13A1 (0.54) | MAPTLMNAGAA | |
| SCHEMBL7436725 | 0.67 | — | — | |
| Adipic Acid SCHEMBL28687655 | 0.67 | LMNA (0.66) | TDP1L3MBTL1MAPTALDH1A1HTT | |
| SCHEMBL25261486 | 0.67 | CYP1A2 (0.54) | CYP1A2CYP2C9HSD17B10ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0731648-B1 | FLAVOURING COMPOSITIONS AND METHOD | FIRMENICH & CIE (CH) | 2003-03-26 | — | — | EP | claimed |
| CN-1136764-A | Flavouring compositions and its preparing method | FIRMENICH & CIE (CH) | 1996-11-27 | — | — | CN | claimed |
| EP-3806661-B1 | USE OF ANTAGONISTS OF T2R54 | FIRMENICH INCORPORATED (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4566459-A2 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | Firmenich Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2025-05-13 | — | — | US | disclosed |
| CN-113194742-B | Antagonists of T2R54, compositions thereof and uses thereof | 弗门尼舍公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | FIRMENICH INCORPORATED (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2024-01-16 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220330591-A1 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2022-10-20 | — | — | US | disclosed |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-04-06 | — | — | US | disclosed |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | SENOMYX INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | SENOMYX INC (US) | 2016-12-29 | — | — | US | disclosed |
| EP-0731648-B1 | FLAVOURING COMPOSITIONS AND METHOD | FIRMENICH & CIE (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-6287620-B1 | Flavor enhancing methods | FIRMENICH SA (CH) | 2001-09-11 | — | — | US | disclosed |
| US-6287620-B1 | Flavor enhancing methods | FIRMENICH SA (CH) | 2001-09-11 | — | — | US | disclosed |
| CN-1136764-A | Flavouring compositions and its preparing method | FIRMENICH & CIE (CH) | 1996-11-27 | — | — | CN | disclosed |
| EP-0731648-A1 | FLAVOURING COMPOSITIONS AND METHOD | FIRMENICH SA (CH) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996010927-A1 | FLAVOURING COMPOSITIONS AND METHOD | FIRMENICH S.A. (CH) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | USP2 4693/4885PABPC1 2889/4885TDP1 2650/4885 |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | USP2 3865/4885PABPC1 2842/4885TDP1 3843/4885 |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | TAS2R5, TAS1R1, TAS2R1 | USP2 3953/4885PABPC1 1859/4885TDP1 1437/4885 |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | USP2 3865/4885PABPC1 2842/4885TDP1 3843/4885 |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | TAS2R50, TAS2R30, TAS2R60 | USP2 3865/4885PABPC1 2842/4885TDP1 3843/4885 |
| US-20220330591-A1 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | TAS2R50, TAS2R30, TAS2R60 | USP2 3865/4885PABPC1 2842/4885TDP1 3843/4885 |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | TRPA1, PDE6G, PDE6D | USP2 3149/4885PABPC1 987/4885TDP1 907/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | USP2 4693/4885PABPC1 2889/4885TDP1 2650/4885 |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | USP2 4285/4885PABPC1 1994/4885TDP1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.